Background: Memorial Sloan Kettering Cancer Center (MSK) created the MSK Cancer Alliance in 2014, a dynamic and bidirectional collaboration with high-quality community providers to enhance access to state-of-the-art cancer care close to home
Search Results
Craig Sauter, W. Jeffrey Baker, Elizabeth Rodriguez, Silvia Willumsen, Barbara Morcerf, Kristi Gafford, Jessica Kennington, Richard Korman, Peter Yu, David Pfister, and Sergio Giralt
Stacey W. MucCullough, David Blaisdell, Jonathan K. Kish, Pat Farmer, JaLyna Laney, Tom Valuck, Natalie Dickson, Johnetta Blakely, Dianna Shipley, Jesus Berdeja, Gregg Shepard, Bertrand M. Anz III, Carolyn Kelsey, Jack Taylor, Chadi Nabhan, Jeffrey F. Patton, and Annette Powers
many community practices integrate specialty pharmacy (SP) services into their practice, patient education, treatment adherence, and visit scheduling coordination are becoming increasingly complex, particularly for treatments with Risk Evaluation and
Nicole A. Arrato, Stephen B. Lo, Clarence A. Coker, Jonathan J. Covarrubias, Tessa R. Blevins, Sarah A. Reisinger, Carolyn J. Presley, Peter G. Shields, and Barbara L. Andersen
were compared with a time-equivalent normative sample, namely, similar individuals from the community also coping with COVID-19 but cancer-free. Having health risk from multiple sources, would patients with NSCLC show greater negative affect, such as
David P. Ryan
The relationship between the academic cancer center and the community cancer center is undergoing a dramatic cultural change. Community hospitals across the Northeast are building fully functional cancer centers where they provide all the services
Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman
relative to standard chemotherapy regimens among 16,233 patients with 6 tumor types who were treated with adjuvant or neoadjuvant chemotherapy regimens currently in widespread use in community oncology practices in the United States. Methods Data
Margaret Tempero
I think it started in 2004. I happened to be President of ASCO at the time and we had a crisis: the Medicare Modernization Act. Cuts in reimbursement for drugs threatened the financial stability of community oncologists around the country. It was
Brad Zebrack, Karen Kayser, Deborah Bybee, Lynne Padgett, Laura Sundstrom, Chad Jobin, and Julianne Oktay
, Comprehensive Community Cancer Program, Community Cancer Program (CCP), or NCI-designated Comprehensive Cancer Center Program (NCIP), which is based on type of facility, services provided, and number of analytic cases per year. 14 Cancer program registries were
Diana I. Brixner, Gary M. Oderda, Nancy A. Nickman, Roy Beveridge, and James A. Jorgenson
Significant changes in Medicare reimbursement for outpatient oncology services were proposed as part of the Medicare Modernization Act of 2003. The purpose of this study was to identify the “true cost” associated with drug-related handling for the preparation and delivery of chemotherapy doses to estimate the impact of changing reimbursement schema by Medicare. Two academic medical outpatient infusion centers and 2 community cancer centers provided data used to estimate all costs (excluding drug cost) associated with the preparation of chemotherapy doses. The data included both fixed costs (drug storage, space, equipment, and information resources) and variable costs (insurance management, inventory, waste management, pharmacy staff payroll, supplies, and shipping). The average cost for the preparation of chemotherapy doses across all sites was $34.27 (range, $32.08–$41.23). A time-and-motion study was also performed to determine what tasks were conducted by pharmacy staff and how much time was spent in the preparation of the top 15 chemotherapeutic drugs and regimens used in the 4 sites. Data from the 4 centers was projected to show that if 3,990,495 million chemotherapy infusions were administered to a national Medicare population in 2003, when multiplied by the average cost of preparation for infusions determined by the current study ($34.27), the estimated total annual cost to Medicare for chemotherapy preparation by pharmacists is $136,754,263.65. The pharmacists spent most of their days (90% or more) performing tasks directly related to the preparation of these agents. These data provide scientific support for the consideration of appropriate reimbursement for chemotherapy services provided by pharmacists to Medicare beneficiaries.
Rie Tamagawa, Shannon Groff, Jennifer Anderson, Sarah Champ, Andrea Deiure, Jennifer Looyis, Peter Faris, and Linda Watson
differed. In the smaller regional and community sites, cancer patient navigators (CPNs) were available for complex distress management. In the larger tertiary cancer centers where the CPN role is not part of the care model, psychologists and social workers
Tarun Chowdary Gogineni
Methods: This is a community based ongoing research, since 01 March 2021. The study protocol was approved by the institutional ethics committee. The study participants were divided in to two groups. Unmarried, 9 – 26 years were in first group and
